THE UNIVERSITY OF MANCHESTER

ANIMAL WELFARE AND ETHICAL REVIEW BODY

Thursday, 28th September 2017



Before the commencement of business the Chair welcomed **excercise**, who was attending his first meeting

1. Minutes

Confirmed: The minutes of the meeting held on 11th July 2017,

2. Matters arising

- 2.1 : Neural basis of tactile behaviour
 - Reported: That the Chairman had confirmed that there was consistency between the Home Office licence application and the AWERB1 form and that the revisions requested by AWERB had been satisfactorily completed and the project approved.

2.2. North West Regional AWERB Hub

Reported: That the next hub meeting would take place on 15th November at the Alderley Park site. A Newsletter had been circulated.

2.3 Retrospective review

Reported: That the BSF was developing a form for retrospective review. This would commence with the review of projects which included a severe protocol

4. Report from the NC3Rs Regional Programme Manager

The NC3Rs Regional Programme Manager reported that:

- Arrangements for the symposium on 30 October were proceeding well. There had been 83 attendees registering and 11 posters submitted
- She had attended two pre-AWERB meetings with applicants and she was discussing how she might formalise her input to the process
- She had attended a mouse handling workshop in London the previous day. The takeaway message from the workshop was that handlers should move away from tail holding to cupping.


5. Arrangements for processing AWERB applications

- Reported: That it was proposed to create SharePoint accounts for AWERB applicants. This was a secure system for storing and viewing important documents. Access to the documents would be restricted to AWERB members, BSF Officers and RGEI administrative staff. It was intended that the documents for each project licence should contain:
 - The AWERB1 form submitted to the AWERB meeting
 - The Home Office licence, locked at the point when the AWERB1 form is finalised
 - The final approved AWERB1 form after revisions sought by the AWERB meeting and sign-off by the Chair and the Establishment Licence Holder
 - Any relevant correspondence, including the approval letter.

The advantage of the system was that it was more secure than sending documents by email and would allow members to see the Home Office licence application if they wished. The intention was that the system would be introduced over the next three months.

6. Report on licences processed 21.06.17 to 05.09.17

Reported: (a) That the following amendments to project licences had been approved by the executive group:



To Delete & Mutate Regions Within the Csf1r Using CRISPR To Develop Novel Mouse Models of Frontotemporal Lobar Degeneration/Motor Neuron Disease

		To Generate an mCherry-Labelled Podocyte Mouse Model			
	(c) gen	, Creation, breeding and maintenance of etically altered rodents:			
	Nor	ne			
	(d) Applications for secondary availability for imaging prurposes				
		Investigation of Anti-Vascular Treatments for Ovarian Cancer (Cancer (Cancer (Cancer)) (Primary at CRUK MI)			
		t for Personal Licences there were 17 new licences, 7 amendments, 11 rendered and 0 renewed.			
Арр	lication for ne	ew Research Project Licence			
7.1		, Maternal Fasting & Offspring Health			
	Considered:	A completed AWERB1 form, with written comments by the NVS, NACWO and NTCO, and NTS.			
	Interviewed:				
	Noted:	(1) That this was a development and continuation of an current licence.(2) Although there was no peer review, there was a letter of support from			
		 (3) There was likely to be stable funding via studentships (4) There would be a limited number of cognitive tests for any one animal (5) Greater clarity was suggested in Replacement section of the NTS. 			
	Resolved:	To recommend approval, subject to re-drafting the Replacement section of the NTS.			
7.2		, Immunogenicity of biologics			
	Considered:	A completed AWERB1 form, with written comments by the NVS, NACWO and NTCO, and NTS.			
	Interviewed:				
	Noted:	(1) That this was a continuation of two licences(2) That "cytokine storm" on page 4 needed an explanation(3) The Refinement section of the NTS needed to be more succinct			
	Resolved:	To recommend approval, subject to an explanation of cytokine storm and a re-draft of the Refinement section of the NTS.			
7.3		, Treatment and Pathology of Neurological Diseases			

7.

Considered: A completed AWERB1 form, with written comments by the NVS, NACWO and NTCO, and NTS.

		Interviewed:		
		Noted:	 (1) This developed and replaced a current 5 year licence (2) AWERB members agreed that your AWERB1 form fulfilled the purposes of the review but found it a hard read. For clarity AWERB and the HO recommend that several smaller, discrete project licences and usually preferable to large and complex licences that attempt to embrace too many areas of experimentation. This is not a requirement for the present application, but something to consider for subsequent applications. (3) It was explained that at 15% weight loss concerns would be raised and closer monitoring introduced; 20% weight loss would be an end point (4) The end points on page 7 would be modified for greater clarity. (5) Numbers appeared not to tie in with Home office licence. 	
		Resolved:	To recommend approval, subject to the above clarifications and transferring the NTS to the new Home Office format.	
	7.4	to infection	, Determining important regulatory pathways that control immune responses	
		Considered:	A completed AWERB1 form, with written comments by the NVS, NACWO and NTCO, and NTS.	
		Interviewed:		
		Noted:	The committee discussed, at some length, end points and the procedures you would have in place to monitor animals that might reach the severe level. The decision of the meeting was to recommend the approval of your project. However, the committee were interested in the frequency of progression to a severe banding in the current project, and would welcome sight of that information when available. In addition, it would be a good idea to provide in the present application, on the basis of experience to date, an estimate of the number of mice that would be expected to progress to a severe banding.	
		Resolved:	To recommend approval, and to ask for the return, in due course, of an amended version of the AWERB1 form, highlighting any changes made.	
8.	Reti	Retirement of		
	This was the last meeting before the second second as NVS . The Chairman and AWERR			

This was the last meeting before **Constitution** retired as NVS. The Chairman and AWERB members paid tribute to the significant contribution he had made to the formulation and development of the Local Ethical Review Process and subsequently AWERB, and more generally to animal welfare issues in the scientific use of animals in the University. He was greatly thanked for his wise guidance to AWERB members who wished him well in his retirement.